Advertisement

Topics

"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma" Drugs and Medication Database

18:45 EST 16th February 2019 | BioPortfolio

Here are the most relevant "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma" Drugs and Medications that we have found in our database.

More Information about "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma" on BioPortfolio

We have published hundreds of Aplidin - Dexamethasone in Relapsed/Refractory Myeloma news stories on BioPortfolio along with dozens of Aplidin - Dexamethasone in Relapsed/Refractory Myeloma Clinical Trials and PubMed Articles about Aplidin - Dexamethasone in Relapsed/Refractory Myeloma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aplidin - Dexamethasone in Relapsed/Refractory Myeloma Companies in our database. You can also find out about relevant Aplidin - Dexamethasone in Relapsed/Refractory Myeloma Drugs and Medications on this site too.

Showing "Aplidin Dexamethasone Relapsed Refractory Myeloma" Drugs and Medications 1–25 of 208

Probably Relevant

Carmustine [zydus pharmaceuticals usa inc.]

These highlights do not include all the information needed to use carmustine for injection, USP safely and effectively. See full prescribing information for carmustine for injection, USP. Carmustine for injection, USP, for intravenous useInitial U.S. Appr

Revlimid [celgene corporation]

These highlights do not include all the information needed to use REVLIMID safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide] capsules, for oral use Initial U.S. Approval: 2005

Bortezomib [fresenius kabi usa, llc]

These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.BORTEZOMIB for injection, for intravenous useInitial U.S. Approval: 2003

Pomalyst [celgene corporation]

These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST. POMALYST (pomalidomide) capsules, for oral useInitial U.S. Approval: 2013

Farydak [novartis pharmaceuticals corporation]

These highlights do not include all the information needed to use FARYDAK safely and effectively. See full prescribing information for FARYDAK. FARYDAK (panobinostat) capsules, for oral use Initial U.S. Approval: 2015

Empliciti [e.r. squibb & sons, l.l.c.]

These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI. EMPLICITI (elotuzumab) for injection, for intravenous useInitial U.S. Approval: 2015

Darzalex [janssen biotech, inc.]

These highlights do not include all the information needed to use DARZALEXsafely and effectively. See full prescribing information for DARZALEX. DARZALEX (daratumumab) injection, for intravenous use Initial U.S. Approval – 2015

Possibly Relevant

Ninlaro [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use NINLARO safely and effectively. See full prescribing information for NINLARO. NINLARO (ixazomib) capsules, for oral use Initial U.S. Approval: 2015

Folotyn [allos therapeutics]

These highlights do not include all the information needed to use FOLOTYN safely and effectively. See full prescribing information for FOLOTYN.FOLOTYN (pralatrexate injection), for intravenous use Initial U.S. Approval: 2009

Kyprolis [onyx pharmaceuticals, inc.]

These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS.    KYPROLIS (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012

Zevalin [spectrum pharmaceuticals, inc.]

These highlights do not include all the information needed to use ZEVALIN safely and effectively. See full prescribing information for ZEVALIN. ZEVALIN® (ibritumomab tiuxetan) injection, for intravenous useInitial U.S. Approval: 2002

Arzerra [novartis pharmaceuticals corporation]

These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. ARZERRA (ofatumumab) injection, for intravenous useInitial U.S. Approval: 2009

Imatinib mesylate [avpak]

Imatinib Mesylate Tablets These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively. See full prescribing information for IMATINIB MESYLATE TABLETS . IMATINIB MESYLATE tablets, for oral use Initial

Zydelig [gilead sciences, inc.]

These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG. ZYDELIG® (idelalisib) tablets, for oral useInitial U.S. Approval: 2014

Beleodaq [spectrum pharmaceuticals, inc.]

These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ. BELEODAQ® (belinostat) for injection, for intravenous useInitial U.S. Approval: 2014

Velcade [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use VELCADE safely and effectively. See full prescribing information for VELCADE. VELCADE (bortezomib) for injection, for subcutaneous or intravenous use Initial U.S. Approval: 2003

Thalomid [celgene corporation]

These highlights do not include all the information needed to use THALOMID safely and effectively. See full prescribing information for THALOMID. THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998

Poteligeo [kyowa kirin, inc.]

These highlights do not include all the information needed to use POTELIGEO safely and effectively. See full prescribing information for POTELIGEO. POTELIGEO (mogamulizumab-kpkc) injection, for intravenous useInitial U.S. Approval: 2018

Tibsovo [agios pharmaceuticals, inc.]

These highlights do not include all the information needed to use TIBSOVO safely and effectively. See full prescribing information for TIBSOVO. TIBSOVO (ivosidenib tablets), for oral use Initial U.S. Approval: 2018

Gemcitabine hydrochloride [bluepoint laboratories]

These highlights do not include all the information needed to use Gemcitabine for Injection safely and effectively. See full prescribing information for Gemcitabine for Injection. Gemcitabine for injection, Powder, Lyophilized, For Solution For Intravenou

Xospata [astellas pharma us, inc.]

These highlights do not include all the information needed to use XOSPATA safely and effectively. See full prescribing information for XOSPATA. XOSPATA (gilteritinib) tablets, for oral useInitial U.S. Approval: 2018

Gemcitabine [hospira, inc.]

These highlights do not include all the information needed to use GEMCITABINE FOR INJECTION safely and effectively. See full prescribing information for GEMCITABINE FOR INJECTION.GEMCITABINE for injection, powder, lyophilized, for solution for intravenous

Gemcitabine [hospira, inc.]

These highlights do not include all the information needed to use GEMCITABINE FOR INJECTION safely and effectively. See full prescribing information for GEMCITABINE FOR INJECTION. GEMCITABINE for injection, powder, lyophilized, for solution for intravenou

Melphalan hydrochloride [sagent pharmaceuticals]

Melphalan Hydrochloride for Injection(For Intravenous Infusion)

Gemcitabine hydrochloride [cipla usa inc.]

These highlights do not include all the information needed to use GEMCITABINE FOR INJECTION safely and effectively. See full prescribing information for GEMCITABINE FOR INJECTION. GEMCITABINE for injection, for intravenous useInitial U.S. Approval: 1996



Advertisement
Quick Search
Advertisement
Advertisement